UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange act of 1934
Date of report (date of earliest event reported): December 5, 2013
RECEPTOS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization) | | 001-35900
(Commission File Number | | 26-4190792
(I.R.S. Employer
Identification No.) |
10835 Road to the Cure, Suite 205
San Diego, California 92121
(858) 652-5700
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On December 5, 2013, Receptos, Inc. issued a press release announcing that it will advance RPC1063, a novel, oral, once daily, selective sphingosine 1-phosphate 1 receptor (S1P1R) modulator candidate being developed for autoimmune indications, into a Phase 3 clinical trial for relapsing multiple sclerosis (RMS) as a result of the interim analysis conducted on the Phase 2 portion of the accelerated, randomized Phase 2/3 study (RADIANCE) for the treatment of RMS. Top-line results for the Phase 2 portion of the study continue to be expected in mid-2014.
The full text of such press release is attached as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
| | |
99.1 | | Press release issued by Receptos, Inc. on December 5, 2013. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 5, 2013 | RECEPTOS, INC. |
| |
| |
| By: | /s/ Christian Waage |
| | Christian Waage |
| | Senior Vice President and General Counsel |
3
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
99.1 | | Press release issued by Receptos, Inc. on December 5, 2013. |
4
